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Background/aim: To analyze postmastectomy radiation therapy (PMRT) utilization and its association with overall survival (OS) in
patients presenting with node-positive breast cancer who are pathologically node-negative (ypN0) after neoadjuvant chemotherapy
(NAC).
Materials and methods: Using the National Cancer Data Base (NCDB), we identified patients diagnosed between 2004 and 2013 with
clinical T1-4 node-positive nonmetastatic breast cancer who received NAC and underwent mastectomy with pathologically negative
lymph node sampling. Multivariable regression models identified factors associated with PMRT use. The Cox proportional hazards
model was used to evaluate predictors of mortality.
Results: The study included 8766 clinically node-positive patients who met the study criteria. PMRT was delivered to 61.5% of patients.
Overall PMRT utilization rate increased over the study period from 54.4% in 2004 to 65.2% in 2011. Predictors of PMRT use included
larger tumor size, increasing clinical N stage, higher grade disease, receipt of hormone therapy, and a greater number of lymph nodes
examined. The unadjusted 5-year OS was 84.1% in the PMRT group and 83.8% in the non-PMRT group (p = NS). PMRT was not
significantly associated with survival on multivariable analysis (hazard ratio [HR] 0.87; 95% confidence interval [CI] 0.73-1.03).
Conclusion: The delivery of PMRT has increased over time in women presenting with clinically node-positive breast cancer who
convert to ypN0 after NAC. While we identified multiple independent socioeconomic and clinical predictors of both PMRT utilization
and survival, PMRT itself was not significantly associated with survival.
Key words: Breast, carcinoma, radiotherapy, chemotherapy

1. Introduction
The benefits of postmastectomy radiation therapy (PMRT)
in locally advanced breast cancer after upfront surgical
resection with or without adjuvant chemotherapy are
well-established [1-3]. The role of PMRT in the setting
of neoadjuvant chemotherapy, however, is an area of
active investigation with limited available randomized
data. There are two ongoing randomized clinical trials
that will ultimately guide locoregional management
[4]. The available data at this time suggests that both
prechemotherapy clinical stage and postchemotherapy
pathologic stage are predictive of locoregional recurrence
[5-8]. Current National Comprehensive Cancer Network
guidelines therefore recommend PMRT for patients
with the residual nodal disease after NAC and state that

PMRT should be “strongly considered” for patients with
the upfront clinical nodal disease who are pathologically
node-negative at the time of surgery (pN0).
With the increasing utilization of NAC among breast
cancer patients, there is likely wide variation in PMRT
practice patterns [9]. The current analysis sought to
utilize the National Cancer Data Base (NCDB) to analyze
PMRT practice patterns and survival outcomes among
patients who are clinically node-positive at diagnosis and
pathologically node-negative after NAC.
2. Materials and methods
2.1. Data source
The NCDB is a national hospital-based cancer registry
that is a joint project of the Commission on Cancer (CoC)

* Correspondence: msayan@bwh.harvard.edu

This work is licensed under a Creative Commons Attribution 4.0 International License.

279

SAYAN et al. / Turk J Med Sci
of the American College of Surgeons and the American
Cancer Society (ACS). It is estimated that 70% of all newly
diagnosed malignancies in the United States are captured
by facilities participating in this registry and reported to the
NCDB. Data are collected by participating cancer program’s
registries and include details on patient characteristics,
cancer staging, tumor histological characteristics, type
of first-course treatment administered, and survival
outcomes. The CoC’s NCDB and the hospitals participating
in the NCDB are the sources of the deidentified data used
in this study. The ACS and CoC have not verified and are
not responsible for the analytic or statistical methodology
employed or the conclusions drawn from these data. This
study utilized deidentified data and was granted human
research exemption from our institutional review board.
2.2. Patient selection
In this study, NCDB registry data from 2004 to 2013
were used to examine the delivery of PMRT to patients
diagnosed with clinical T1-4 node-positive breast
cancer (American Joint Committee on Cancer Staging
Manual, sixth or seventh edition) who received NAC
and underwent mastectomy with pathologically negative
lymph nodes. Patients with clinical or pathologic evidence
of distant metastatic disease, those with bilateral breast
cancer, those who received intraoperative therapies, and
those who did not receive any treatment at the reporting
facility were excluded.
2.3. Treatments
NAC was defined by an interval from initiation of
chemotherapy to surgery of 80 to 270 days. PMRT was
defined as delivery of 45 Gray (Gy) or more of external
beam radiotherapy to the chest wall with or without
regional nodal irradiation. PMRT was required to start
between 15 and 180 days after surgery. While the number
of lymph nodes removed was reported in the NCDB, the
axillary surgery type (sentinel lymph node biopsy vs.
axillary dissection), the presence or absence of extranodal
extension, and specific lymph node target volumes
(axillary vs. supraclavicular vs. internal mammary lymph
nodes) were not specified in the NCDB.
2.4. Statistical analysis
Chi-square tests were used to compare patient demographic,
facility, clinicopathologic, and treatment details between
patients who did and did not receive PMRT. Multivariate
logistic regression was used to identify predictors of PMRT
utilization. Five-year OS was estimated using the KaplanMeier method. Factors associated with mortality were
identified using the Cox proportional hazards model. The
patient, facility, and tumor level variables were considered
in the analyses. A landmark of 180 days from surgery was
used for survival analyses.
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3. Results
A total of 8,766 breast cancer patients diagnosed between
2004 and 2013 with clinical T1-4 node-positive disease
who received NAC and underwent mastectomy with
pathologically negative lymph node sampling were
identified. PMRT was received by 61.5% of these patients
(Figure 1). Most patients (78.2%) had clinical N1 disease
prior to NAC. Patients with clinical N2 and N3 were 13.4%
and 8.5%, respectively. Prior to NAC, 53.4% of the patients
had clinical T1-2 and 46.6% had clinical T3-4 disease.
After NAC, 92.5% of the patients had pathologic T0-2
disease and 7.5% had pathologic T3-4 disease.
Figure 2 demonstrates trends in PMRT use between
2004 and 2013. Overall PMRT utilization rate increased
over the study period from 54.4% in 2004 to 65.2% in
2011. The rate of increase varied depending upon the year.
The largest increase in PMRT utilization was seen between
2004 and 2005, from 54.4% to 60.2%.
Table 1 shows the predictors of PMRT utilization
on multivariable analysis. Older age, higher CharlsonDeyo comorbidity score, insurance with Medicaid/
Medicare, further distance from the treatment center,
and reconstruction were all associated with decreased
utilization of PMRT. Patients with higher clinical T stage,
higher clinical N stage, or higher-grade disease were more
likely to receive PMRT, as were patients who received
hormone therapy and patients with greater numbers
of lymph nodes examined. Race, income, facility type
(academic vs. nonacademic), pathologic T stage, and
laterality were not significantly associated with PMRT on
multivariable analysis.
The Median follow-up was 39 months. Unadjusted
5-year overall survival was not significantly different at
84.1% in the PMRT group and 83.8% in the non-PMRT
group (Figure 3). Table 2 lists the predictors of mortality
according to multivariable analysis for all patients included
in this study. Older age, increasing clinical or pathologic T
stage, increasing clinical N stage, and Medicaid/Medicare
insurance were associated with decreased survival.
Patients who received hormone therapy or those with
greater numbers of lymph nodes examined had improved
survival. PMRT, race, Charlson-Deyo comorbidity score,
income, facility type (academic vs. non-academic),
laterality, and grade were not significantly associated with
survival on multivariable analysis. Notably, PMRT was not
significant associated with survival (multivariable hazard
ratio [HR] 0.87; 95% confidence interval [CI] 0.73-1.03).
4. Discussion
With this study using a large population-based database,
we have demonstrated that the utilization of PMRT
increased in clinically node positive breast cancer patients
who converted to pathologically node negative after NAC.
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Figure 1. CONSORT diagram for 8766 patients with nonmetastatic invasive breast cancer who were clinically node-positive,
received neoadjuvant chemotherapy, underwent mastectomy, and were pathologically node-negative.

Figure 2. The use of postmastectomy radiation therapy is illustrated by the year
of diagnosis.
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Table 1. Predictors of postmastectomy radiation therapy receipt
for all patients.

Variable*

Odds ratio

95% Cl

p

≤50

1.00

Reference

>50

0.87

0.78-0.98

0-1

1.00

Reference

2

0.64

0.42-0.99

Private insurance

1.00

Reference

Medicaid/Medicare

0.66

0.58-0.75

>50

1.00

Reference

≤50

0.70

0.58-0.85

No

1.00

Reference

Yes

1.80

1.60-2.02

cT1-2

1.00

Reference

cT3-4

1.83

1.64-2.06

cN1

1.00

Reference

cN2

1.53

1.30-1.81

<0.001

cN3

2.02

1.63-2.49

<0.001

<10

1.00

Reference

≥10

1.22

1.09-1.36

G1

1.00

Reference

G2

1.41

1.02-1.96

0.04

G3

1.47

1.02-2.02

0.02

No

1.00

Reference

Yes

0.76

0.67-0.86

Age, y
0.018

Charlson-Deyo score
0.046

Primary payer
<0.001

Distance, miles
<0.001

Hormone therapy
<0.001

Clinical T stage
<0.001

Clinical N stage

No. LNs examined
<0.001

Grade

Reconstruction
<0.001

*Only significant variables are shown. Race, income, facility type
(academic vs nonacademic), pathologic T stage, and laterality
were not significantly associated with PMRT utilization.

PMRT utilization rates ranged from 54.4% to 65.2%,
peaking in 2011. Though multiple independent predictors
of PMRT utilization and survival were identified, PMRT
itself was not significantly associated with survival.
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Utilization of NAC has been increasing. Potential
benefits include pathologic down-staging, avoiding
delays in systemic therapy, and upfront treatment of
micrometastatic disease [9-11]. These advantages,
particularly in the setting of complete pathological nodal
response, create a unique challenge for clinicians in
determining the optimal subsequent locoregional therapy.
While we await results of the ongoing NSABP B51/RTOG
1304 randomized clinical trial investigating the benefit of
regional nodal irradiation in this patient population, the
currently available data is largely limited by its retrospective
nature and somewhat conflicting results.
One observation from our study is that PMRT was not
significantly associated with survival. Similarly, Shim et al.
analyzed the outcomes of 151 patients with clinical stage II
(60%) and III (40%) breast cancer who were treated with
NAC followed by mastectomy with complete pathological
nodal response [12]. Of these, 105 received PMRT and
46 did not. The 5-year LRR-free survival was 98.1% with
PMRT and 92.3% without PMRT, and the 5-year OS was
similar at 93.3% vs. 89.9%. Le Scodan et al. also identified
134 women with clinical stage II (62%) and III (38%)
breast cancer treated with NAC and mastectomy who were
pathologically node-negative. PMRT was delivered to 78
patients. The 10-year LRR-free survival and OS rates were
similar among patients who received PMRT and those who
did not: 96.2% vs. 86.8% (p = 0.18) and 77.2% vs. 87.7%
(p = 0.15), respectively [13]. Both studies reported that
PMRT was not a prognostic factor on multivariate analysis.
However, a study from MD Anderson Cancer Center
showed that PMRT was associated with improved diseasespecific and OS in breast cancer patients who achieved
complete pathological response after NAC [14]. In this
study, McGuire et al. identified 106 patients with clinical
stage I (2%), II (31%), and III (66%) disease treated with
NAC and mastectomy who had a complete pathological
response. PMRT was delivered to 72 patients. In patients
with clinical stage III disease, the 10-year LRR and OS
rates were higher with PMRT compared to those without
PMRT: 7.3% vs 33.3% (p = 0.040) and 77.3% vs 33.3% (p =
0.0016), respectively. However, the limited sample size and
unbalanced baseline characteristics between the groups
bring into question the statistical power of the reported
study observations.
While the result of the ongoing NSABP B51/RTOG
1304 randomized clinical trial is pending, an unquantifiable
factor that may have contributed to the increasing use of
PMRT during the latter period of the study was the effect
of the NCICMA.20 and EORTC 22922 trials. These trials
examined the role of regional nodal irradiation in patients
who had breast cancer with 1 to 3 positive lymph nodes.
In 2010 and 2011, the preliminary findings from those
trials suggesting that regional nodal irradiation improved
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Figure 3. Kaplan-Meier 5-year survival curves for all patients stratified by
PMRT utilization.
Table 2. Predictors of survival for all patients.
Variable*
Age, y
≤50
>50
Primary payer
Private insurance
Medicaid/Medicare
Hormone therapy
No
Yes
Clinical T stage
cT1-2
cT3-4
Clinical N stage
cN1
cN2
cN3
Pathologic T stage
cT1-2
cT3-4
No. LNs examined
<10
≥10
PMRT
No
Yes

Hazard ratio

95% Cl

p

1.00
1.34

Reference
1.12-1.61

0.002

1.00
1.40

Reference
1.16-1.69

<0.001

1.00
0.56

Reference
0.50-0.69

<0.001

1.00
1.30

Reference
1.08-1.56

0.006

1.00
1.34
1.38

Reference
1.08-1.67
1.04-1.82

0.007
0.024

1.00
1.61

Reference
1.27-2.03

<0.001

1.00
0.70

Reference
0.59-0.83

<0.001

1.00
0.87

Reference
0.73-1.03

0.115

*Only significant variables and PMRT are shown. Race, CharlsonDeyo score, income, facility type (academic vs. nonacademic),
laterality, and grade were not significantly associated with
survival.

disease-free survival and overall survival [15, 16]. While
the majority of patients included in these trials underwent
breast conserving therapy, these results are often
extrapolated to patients who undergo mastectomy. The
findings may have encouraged more radiation oncologists
to pursue PMRT for women who had T1-T2 primary
tumors with 1 to 3 positive lymph nodes. Furthermore, an
important observation of our study was that the high rate
of cN1 disease in the study population (78.2%) which may
have contributed to no survival benefits with PMRT.
In the absence of randomized data, retrospective
studies suggest that the initial extent of disease clinically
and the response of axillary lymph nodes to NAC are
important factors to consider when considering adjuvant
PMRT. However, breast cancer patients who receive
NAC represent a heterogeneous group, ranging from
locally advanced, inoperable to early-stage, operable
disease. Furthermore, different response rates to NAC
also contribute to the heterogeneity of this patient
population. Therefore, it is difficult to generalize treatment
recommendations across such a diverse population. It is
also not clear how to prioritize clinical stage at the time of
presentation and residual pathologic disease burden after
NAC in the decision-making process. It is likely this lack
of clarity that contributes to the varying PMRT practice
patterns seen in the present analysis.
There are several important limitations of our
present analysis. Details regarding chemotherapy agents
administered, the use of targeted therapies, the use
of sentinel lymph node biopsy, radiation lymph node
volumes, and biological characteristics of the tumor such
as ER, PR, Her2, and Ki-67 status were not available.
Additionally, the NCDB does not include data on LRR
and disease-free survival, which is particularly relevant

283

SAYAN et al. / Turk J Med Sci
for our study population. Additional limitations of our
study include the retrospective nature of the data, patient
selection and institutional reporting bias, and a relatively
short period of follow-up.
In conclusion, we report that about 60% of patients
with clinically node-positive breast cancer who were
ypN0 after NAC received PMRT. We identified multiple
independent socioeconomic and clinical predictors of

PMRT utilization. PMRT was not significantly associated
with survival.
Informed consent
Since the data used in this study were extracted from
the deidentified NCDB file, no informed consent was
obtained, and the research was considered exempt from
institutional review board approval.
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